This new PBS Newshour video takes a look at a new exhibit at the Air and Space Museum celebrating NASA's space art program.

The post PBS Newshour takes a look at the new National Air and Space Museum exhibition “NASA | ART: 50 Years of Exploration” appeared first on Smithsonian Insider.

Digging up early human and animal remains from the field in Africa, performing examination and publishing research about her findings, then enticing and educating the public about the implications are all in a week's work for Briana Pobiner.

The post Meet Our Scientist–Briana Pobiner, human origins researcher at the National Museum of Natural History appeared first on Smithsonian Insider.

Tom Crouch, Senior curator in the National Air and Space Museum's Aeronautics Division, discusses Thaddeus Lowe and the birth of American aerial reconnaissance during the Civil War. This presentation was recorded on May 11, 2011 on the National Mall.

The post Tom Crouch, Senior curator in the National Air and Space Museum’s Aeronautics Division, discusses Thaddeus Lowe and the birth of American aerial reconnaissance appeared first on Smithsonian Insider.

Kari Bruwelheide, forensic anthropologist at the Smithsonian's National Museum of Natural History, discusses how she came to work at the museum, the power of human remains and the information that bones can contain. She and her colleagues continue to discover new ways to interpret evidence from bones and burials.

The post Kari Bruwelheide, forensic anthropologist at the Smithsonian’s National Museum of Natural History, discusses the power of bones. appeared first on Smithsonian Insider.

Meet the Smithsonian's Matthew Carrano, curator of Dinosauria at the Smithsonian's National Museum of Natural History in Washington, D.C. Matthew studies all things dinosaur, but focuses on the evolutionary history of predatory (meat eating) dinosaurs.

The post Meet Our Scientist: Matthew Carrano, curator of dinosauria at the Smithsonian’s National Museum of Natural History appeared first on Smithsonian Insider.

Members of the Human Origins Program team at the Smithsonian's National Museum of Natural History describe why they love their job.

The post Human Origins Program team members at the National Museum of Natural History on why they love their job appeared first on Smithsonian Insider.

The post Learn about the ash that comes from volcanoes with Dr. Liz Cottrell, a geologist from the National Museum of Natural History appeared first on Smithsonian Insider.

The post Natural History Museum curator Nick Pyenson explains how scientists know what dinosaurs and other extinct animals ate appeared first on Smithsonian Insider.

The post Museum Conservation Institute research scientist Ed Vicenzi discusses his work analyzing daguerreotypes appeared first on Smithsonian Insider.

The post Smithsonian conservators open 2001 Jim Thorpe Wheaties Box from the Smithsonian’s National Museum of the American Indian appeared first on Smithsonian Insider.

Don your clean room clothing and take a glimpse into the Smithsonian's new Antarctic meteorite storage facility in Suitland, Md., where all of the Antarctic meteorites in the national collection are kept under tight security and tight airlocks.

The post Glimpse into the Smithsonian National Museum of Natural History’s new meteorite storage facility appeared first on Smithsonian Insider.

One of Italy’s greatest treasures, Leonardo da Vinci’s Codex on the Flight of Birds, will be exhibited at the National Air and Space Museum from […]

The post da Vinci’s “Codex on the Flight of Birds” will be on view at Air and Space Museum, Sept. 13-Oct. 22. appeared first on Smithsonian Insider.

Ever wonder what it’s like to be an endocrinologist at the National Zoo? Meet Sarah Putman, endocrinologist at the Smithsonian Conservation Biology Institute.

The post Meet the Smithsonian’s poop sleuth appeared first on Smithsonian Insider.

Cooper Hewitt, Smithsonian Design Museum, the only museum in the U.S. devoted exclusively to design, reopens after a 3-year makeover with 60 percent more exhibition […]

The post Smithsonian Design Museum in NYC Reopens with High Tech Makeover appeared first on Smithsonian Insider.

The Smithsonian’s National Museum of Natural History released a new mobile app “Skin and Bones” Jan. 13. The free app is available for download in […]

The post Museum specimens come to life in new “Skin and Bones” mobile app appeared first on Smithsonian Insider.

Get a look behind the scenes as we installed “Outside the Spacecraft: 50 Years of Extra-vehicular Activity,” a new exhibition on view at the Museum […]

The post “Outside the Spacecraft,” a new exhibition at the Air and Space Museum appeared first on Smithsonian Insider.

NASA’s Kepler mission is responsible for history’s first detection of Earth-sized planets orbiting other suns in their temperate “habitable zones.” The team in charge of […]

The post NASA’s Kepler mission receives National Air and Space Museum’s highest group honor appeared first on Smithsonian Insider.

This video highlights the mass-digitization of the National Postal Museum’s Sidney N. Shure Collection of Israeli and Palestinian stamps and covers.

The post National Postal Museum Rapid Capture Project appeared first on Smithsonian Insider.

The National Air and Space Museum will reopen the “Boeing Milestones of Flight Hall” July 1 in conjunction with the museum’s 40th anniversary. The two-year […]

The post Air and Space Museum’s “Boeing Milestones of Flight Hall” Reopens July 1! appeared first on Smithsonian Insider.

Gwen Ifill sat down with Lonnie Bunch, the director of the Smithsonian Museum of African American History and Culture, which is due to open this […]

The post PBS Newshour interview with Lonnie Bunch, African American Museum director appeared first on Smithsonian Insider.

National Museum of African American History and Culture grand opening Sept. 24, 2016.

The post Grand Opening of the National Museum of African American History and Culture appeared first on Smithsonian Insider.

Happy Holidays from the Smithsonian’s National Air and Space Museum!

The post Happy Holidays from the National Air and Space Museum appeared first on Smithsonian Insider.

The post President Trump press conference at National Museum of African American History and Culture appeared first on Smithsonian Insider.

Get a quick tutorial on how to upload a story about your local culture and experiences to the Smithsonian’s storytelling website, located www.museumonmainstreet.org Museum on […]

The post Posting Your Story to Smithsonian’s Museum on Main Street Website appeared first on Smithsonian Insider.

Explore a “day in the life” of the Smithsonian American Art Museum, the nation’s first collection of American art and home to one of the […]

The post A “day in the life” of the Smithsonian American Art Museum appeared first on Smithsonian Insider.

Smithsonian staff gathered on Thursday, June 1 outside the National Museum of African American History and Culture to show their support and listen to Director […]

The post Smithsonian staff rally to support African American History Museum after noose incident appeared first on Smithsonian Insider.

Internationally renowned artist Mark Bradford will debut one of his largest works to date with “Pickett’s Charge,” a monumental new commission that spans nearly 400 […]

The post Mark Bradford: Pickett’s Charge at the Hirshhorn Museum appeared first on Smithsonian Insider.

Monday, April 30 marks planetary geologist Dr. Ellen Stofan’s first day as the new John and Adrienne Mars Director of the National Air and Space […]

The post Ellen Stofan leads Air and Space Museum appeared first on Smithsonian Insider.

Dried specimens of nearly 800 flowering plants were acquired by the Botany Department of the Smithsonian’s National Museum of Natural History from the National Botanical Research Institute in Windhoek, Namibia, Africa. The collection includes nearly 160 specimens from the Compositae, or sunflower family.

The post Namibian specimens come to the herbarium of the National Museum of Natural History appeared first on Smithsonian Insider.

Since its doors first opened in 1910, the National Museum of Natural History has inspired curiosity and learning about the natural world and our place […]

The post Slide Show: Smithsonian’s National Museum of Natural History is 100! appeared first on Smithsonian Insider.

The move enhances coordination efforts for the 46-plot research network, which partners with more than 75 institutions in 21 countries.

The post Global forest science research center moves from Harvard to the National Museum of Natural History, Washington, D.C. appeared first on Smithsonian Insider.

Engineers shouldn’t have to reinvent the wheel—or wings, or sonar systems—when mother nature has already done much of the heavy design work. In fact, finding […]

The post Next Engineering Revolution Is Hiding in Museum Collections appeared first on Smithsonian Insider.

An intuitive method is presented for detecting pseudosymmetries in Z' > 1 cases as a complement to well-proven strategies already available in the literature. It is based in the simple idea that the mid-points between equivalent atoms in symmetrically related mol­ecules are disposed according to simple well-known patterns, which are easily recognizable by optical inspection. A number of Z' = 4 cases in the literature are analyzed, which allows some of the potentialities of the method to be revealed.

(The Paypers) Scrive, a Nordic e-sign and eID services provider, and

Ingenico Group,

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Use of protective face coverings will be one of many strategies used to slow or prevent transmission of the flu virus in the event of a pandemic, even though scientific evidence about the effectiveness of inexpensive, disposable medical masks and respirators against influenza is limited.

Each year, tens of millions of Americans, young and old, choose to learn about science in informal ways -- by visiting museums and aquariums, attending after-school programs, pursuing personal hobbies, and watching TV documentaries, for example.

Evidence exists that people who lived or worked at Camp Lejeune Marine Base in North Carolina between the 1950s and 1985 were exposed to the industrial solvents tricholorethylene (TCE) or perchloroethylene (PCE) in their water supply, but strong scientific evidence is not available to determine whether health problems among those exposed are due to the contaminants, says a new report from the National Research Council.

Efforts to convert civilian research reactors from weapon-grade highly enriched uranium (HEU) to low enriched uranium (LEU) fuels are taking significantly longer than anticipated, says a congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

Joint statements from the national science academies of the G7 nations were delivered today to the Italian government in advance of the G7 Summit to be held in Taormina, Italy, at the end of May.

The U.S. is losing ground in a second laser revolution of highly intense, ultrafast lasers that have broad applications in manufacturing, medicine, and national security, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Current federal safety regulations for small distribution systems used for propane and other liquefied petroleum gases (LPGs) should be improved for clarity, efficiency, enforceability, and applicability to risk, says a new reportfrom the National Academies of Sciences, Engineering, and Medicine.